Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report

Share

AbbVie’s Humira is topping industry sales, but by 2025, the drug will fall to the No. 6 spot in best-selling meds, according to a new forecast from GlobalData. Analysts expect Merck’s Keytruda to reach $22.5B in 2025 sales, becoming the new industry leader. See how GlobalData’s forecast affects the rest of the rankings in the chart below:

Read the full report at fiercepharma.com…

Share

Comments are closed.

More in Ashton Tweed Connection
Alexion inks deal to acquire Achillion for $930M upfront

Alexion has struck a deal to buy Achillion for $930M. The takeover will give Alexion two clinical-phase medicines in development...

Close